CN109096387B - 聚乙二醇化的oxm变体 - Google Patents

聚乙二醇化的oxm变体 Download PDF

Info

Publication number
CN109096387B
CN109096387B CN201811001898.9A CN201811001898A CN109096387B CN 109096387 B CN109096387 B CN 109096387B CN 201811001898 A CN201811001898 A CN 201811001898A CN 109096387 B CN109096387 B CN 109096387B
Authority
CN
China
Prior art keywords
oxm
peg
fms
another embodiment
fmoc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201811001898.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN109096387A (zh
Inventor
U·E·菲马
O·赫什科维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of CN109096387A publication Critical patent/CN109096387A/zh
Application granted granted Critical
Publication of CN109096387B publication Critical patent/CN109096387B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201811001898.9A 2012-06-04 2013-06-04 聚乙二醇化的oxm变体 Active CN109096387B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655367P 2012-06-04 2012-06-04
US61/655,367 2012-06-04
CN201380040700.7A CN104684576B (zh) 2012-06-04 2013-06-04 聚乙二醇化的oxm变体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380040700.7A Division CN104684576B (zh) 2012-06-04 2013-06-04 聚乙二醇化的oxm变体

Publications (2)

Publication Number Publication Date
CN109096387A CN109096387A (zh) 2018-12-28
CN109096387B true CN109096387B (zh) 2021-11-30

Family

ID=49711501

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811001898.9A Active CN109096387B (zh) 2012-06-04 2013-06-04 聚乙二醇化的oxm变体
CN201380040700.7A Active CN104684576B (zh) 2012-06-04 2013-06-04 聚乙二醇化的oxm变体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380040700.7A Active CN104684576B (zh) 2012-06-04 2013-06-04 聚乙二醇化的oxm变体

Country Status (17)

Country Link
US (3) US10537646B2 (enExample)
EP (1) EP2854838B1 (enExample)
JP (2) JP6290193B2 (enExample)
KR (1) KR102092025B1 (enExample)
CN (2) CN109096387B (enExample)
AU (2) AU2013273135B2 (enExample)
CA (1) CA2875599C (enExample)
CL (1) CL2014003307A1 (enExample)
CO (1) CO7160097A2 (enExample)
EA (1) EA201492269A1 (enExample)
HK (1) HK1209045A1 (enExample)
IL (1) IL236034B (enExample)
IN (1) IN2015DN00003A (enExample)
MX (1) MX362432B (enExample)
PE (1) PE20150181A1 (enExample)
SG (2) SG11201408054RA (enExample)
WO (1) WO2013183052A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
MX2014012625A (es) 2012-04-19 2015-05-15 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
CN109096387B (zh) 2012-06-04 2021-11-30 奥普科生物制品有限公司 聚乙二醇化的oxm变体
BR112015011583B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Métodos para aumentar o tamanho ou volume hidrodinâmico de hormônio de crescimento humano, método para aumentar o peso molecular aparente de um polipeptídeo e método para aumentar a meia-vida de um polipeptídeo
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
SG11201704706RA (en) 2014-12-10 2017-07-28 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
JP2018517697A (ja) * 2015-05-29 2018-07-05 オプコ バイオロジクス リミテッド ペグ化オキシントモジュリン変異体
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
WO2017075583A2 (en) * 2015-10-30 2017-05-04 The Research Foundation For The State University Of New York Oxyntomodulin analogs and methods of making and using same
CN113546159B (zh) * 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
WO2017212494A1 (en) * 2016-06-09 2017-12-14 Opko Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2018011799A1 (en) 2016-07-11 2018-01-18 Opko Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素类似物
US11236142B2 (en) * 2017-08-16 2022-02-01 Dong-A St Co., Ltd. Acylated oxyntomodulin peptide analog
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
EP3924369A1 (en) 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
WO2025184364A1 (en) * 2024-03-01 2025-09-04 University Of Notre Dame Du Lac Self-assembling depots of adjuvant peptide therapies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213209A (zh) * 2005-06-13 2008-07-02 皇家创新有限公司 新颖化合物及它们对进食行为的影响
CN101389648A (zh) * 2006-02-22 2009-03-18 默克公司 肽胃泌酸调节素衍生物
CN101878036A (zh) * 2007-11-29 2010-11-03 韩美药品工业株式会社 包含促胰岛素释放肽缀合物的治疗肥胖相关疾病的药物组合物
WO2012167251A1 (en) * 2011-06-02 2012-12-06 Prolor Biotech Inc. Long-acting glp-1/glucagon receptor agonists

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
ATE110571T1 (de) 1988-05-06 1994-09-15 Toray Industries Stabile interferon-beta-zusammensetzung.
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JP3148298B2 (ja) 1991-09-02 2001-03-19 帝人株式会社 軽量複合成形物の製造法
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
EP0795562A4 (en) 1994-11-07 2000-08-09 Kyowa Hakko Kogyo Kk NEW OXYNTOMODULIN
NZ313769A (en) 1995-08-10 2000-02-28 Kazunori Kataoka block polymer having a functional group presented on each end
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
ATE399567T1 (de) 1998-04-28 2008-07-15 Serono Lab Peg konjugate von lhrh analogen
US6617276B1 (en) 2000-07-21 2003-09-09 Johnson Matthey Public Limited Company Hydrocarbon trap/catalyst for reducing cold-start emissions from internal combustion engines
IL139400A0 (en) 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
KR100870013B1 (ko) 2002-08-27 2008-11-21 삼성전자주식회사 박막 트랜지스터 어레이 기판 및 그 제조 방법
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP4698579B2 (ja) 2003-04-08 2011-06-08 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 可逆的ｐｅｇ化薬物
SI1891105T1 (sl) * 2005-06-13 2012-07-31 Imp Innovations Ltd Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
TWM345876U (en) 2008-06-17 2008-12-01 Yong-Xuan Ji Auxiliary device for mobile engine
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
MY150536A (en) 2009-03-20 2014-01-30 Hanmi Science Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
WO2012101619A1 (en) 2011-01-24 2012-08-02 Ben Gurion University Of The Negev Research And Development Authority A method for evaluating a mental disorder
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
PH12013502517A1 (en) 2011-06-17 2014-01-20 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
MX2014012625A (es) 2012-04-19 2015-05-15 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
CN109096387B (zh) 2012-06-04 2021-11-30 奥普科生物制品有限公司 聚乙二醇化的oxm变体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101213209A (zh) * 2005-06-13 2008-07-02 皇家创新有限公司 新颖化合物及它们对进食行为的影响
CN101389648A (zh) * 2006-02-22 2009-03-18 默克公司 肽胃泌酸调节素衍生物
CN101878036A (zh) * 2007-11-29 2010-11-03 韩美药品工业株式会社 包含促胰岛素释放肽缀合物的治疗肥胖相关疾病的药物组合物
WO2012167251A1 (en) * 2011-06-02 2012-12-06 Prolor Biotech Inc. Long-acting glp-1/glucagon receptor agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Long Acting Reversible PEGylated Oxyntomodulin - MOD - 6030;PROLOR BIOTECH;《5th Diabetes Drug Discovery & Development Conference》;20120419;全文 *
聚乳酸-b-聚(Nε -苄氧羰基-L-赖氨酸)-b-聚乙二醇的合成与表征;向莉等;《高分子学报》;20101231(第6期);全文 *
胃泌酸调节素研究进展;罗艳娜等;《动物医学进展》;20090420(第04期);全文 *
选择性聚乙二醇化赖氨酸的合成;汪林发等;《合成化学》;20101231;第18卷(第6期);全文 *

Also Published As

Publication number Publication date
US10537646B2 (en) 2020-01-21
JP6290193B2 (ja) 2018-03-07
AU2018201623B2 (en) 2019-08-29
AU2018201623A1 (en) 2018-03-29
CN109096387A (zh) 2018-12-28
IL236034B (en) 2019-02-28
IN2015DN00003A (enExample) 2015-05-22
CL2014003307A1 (es) 2015-04-10
IL236034A0 (en) 2015-01-29
WO2013183052A1 (en) 2013-12-12
EA201492269A1 (ru) 2016-02-29
JP2015520184A (ja) 2015-07-16
CA2875599A1 (en) 2013-12-12
JP6549741B2 (ja) 2019-07-24
MX362432B (es) 2019-01-17
US20180050113A1 (en) 2018-02-22
AU2013273135A1 (en) 2015-01-22
KR102092025B1 (ko) 2020-03-24
AU2013273135B2 (en) 2017-12-07
SG11201408054RA (en) 2015-01-29
CO7160097A2 (es) 2015-01-15
US20150119320A1 (en) 2015-04-30
PE20150181A1 (es) 2015-02-28
HK1209045A1 (en) 2016-03-24
US20150148289A1 (en) 2015-05-28
US9821070B2 (en) 2017-11-21
CA2875599C (en) 2020-08-18
EP2854838A4 (en) 2016-05-04
MX2014014890A (es) 2015-06-17
SG10201702228QA (en) 2017-04-27
EP2854838B1 (en) 2018-10-17
CN104684576B (zh) 2019-08-06
JP2018100279A (ja) 2018-06-28
CN104684576A (zh) 2015-06-03
EP2854838A1 (en) 2015-04-08
KR20150021087A (ko) 2015-02-27

Similar Documents

Publication Publication Date Title
CN109096387B (zh) 聚乙二醇化的oxm变体
KR102092206B1 (ko) 장기-작용성 glp-1/글루카곤 수용체 작용제
US10166295B2 (en) Pegylated OXM variants
EP3302571B1 (en) Pegylated oxyntomodulin variants
US20190160152A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant